Imaging
Scans across centers, hospitals, CDs, and portals.
VisitVizor
Loading your workspace
Preparing your dashboard, records, and imaging tools.
VisitVizor
Preparing your dashboard, records, and imaging tools.
VisitVizor LEAD Research Initiative
The estimated share of cancer patients who participate in treatment trials.
The other 92.9% still have scans, labs, medications, treatment changes, side effects, outcomes, and lived experience. But most of that real-world journey never becomes research-ready evidence.
Source: Unger et al., Journal of Clinical Oncology, 2024. National estimate of cancer treatment trial participation based on Commission on Cancer accreditation data.
Treatment trials
A small visible segment of the broader real-world cancer journey.
7.1%
estimated treatment trial participation
7.1%
Treatment trial participants
92.9%
Real-world journeys outside treatment trials
Real-world journey
Cancer care happens across doctors, hospitals, imaging centers, labs, medications, visits, and time. Each piece may exist somewhere - but rarely together.
Scans across centers, hospitals, CDs, and portals.
Results from different networks and moments in care.
Treatment starts, stops, dose changes, and combinations.
Symptoms, tolerability, and daily treatment burden.
How scans, labs, and clinical status change over time.
What happened after treatment decisions were made.
Movement between doctors, sites, and care settings.
What families observe between visits and over time.
Fragmented evidence
Healthcare has records, claims, registries, reports, portals, and imaging archives. But no single system usually has the full patient story.
Essential and controlled, but limited to selected participants.
Rich inside one institution, but incomplete across outside care.
Broad, but weak on imaging response, symptoms, and clinical nuance.
Useful for defined questions, but often narrow, manual, and incomplete over time.
The problem is not that the evidence does not exist. The problem is that it has never been connected around the patient.
VisitVizor inversion
VisitVizor starts with the patient-owned timeline. Imaging, labs, medications, records, and outcomes are organized around the person - not trapped inside one institution. With patient consent, that longitudinal story can become de-identified evidence for discovery.
Traditional model
VisitVizor LEAD model
Consent and trust
LEAD is not built on hidden reuse of patient data. A VisitVizor account exists first for the patient's own care. Research participation is separate, optional, and patient-directed.
Your VisitVizor account exists first to help you and your care team keep the story together.
You choose whether your de-identified longitudinal data can contribute to LEAD.
Research datasets preserve analytical value while removing personally identifying information.
Patient-directed research projects
LEAD is not one giant research database where patient data disappears. It is a patient-directed research network. Different groups can sponsor or launch specific projects - including accredited institutions, academic researchers, disease foundations, advocacy groups, care organizations, and, where appropriate, commercial partners.
VisitVizor provides continuity, consent, and de-identification infrastructure. Patients direct participation.
A specific question, sponsor, and participation pathway.
The project is visible before a patient chooses to participate.
The patient chooses where de-identified data can go.
De-identified longitudinal evidence can be analyzed at scale.
University and hospital researchers studying real-world outcomes.
Patient communities asking questions that matter to their disease area.
Mission-driven organizations funding discovery and patient benefit.
Public-interest research efforts identified by the VisitVizor community.
Clearly disclosed industry-sponsored projects where patients choose whether to participate.
Possible project sponsors
Academic Institution
Researcher
Advocacy Group
Foundation
VisitVizor-supported Project
Commercial Sponsor
The patient decides.
VisitVizor does not use patient data for research by default. Research participation happens only when a patient chooses to direct de-identified data to a specific project or approved research pathway.
If a patient community sees an unanswered question, that community can help bring attention to the need, connect with a qualified researcher, and sponsor or support a LEAD project.
VisitVizor's first priority is to support open, publishable research with qualified institutions and researchers. Early academic, nonprofit, or public-interest projects may be supported with little or no platform fee while the network is being built. At larger scale, or for commercial use, platform fees may apply. Commercial sponsorship should be clearly disclosed before patients choose whether to participate.
Patients decide where their data goes.
What LEAD makes possible
Which therapies work for which real-world patients?
How does tumor burden change relative to medications, labs, and dose changes?
How do treatment changes affect side effects and outcomes?
Why do some patients respond unusually well while others do not?
Where do delays, fragmentation, or missing records affect outcomes?
The patterns may already exist. They have just never been connected with patient consent at scale.
How LEAD works
Step 1
Imaging, labs, medications, and records are added to a patient-controlled VisitVizor account.
Step 2
Data is organized into a longitudinal medical history.
Step 3
Research participation is optional and patient-directed.
Step 4
Qualified research partners can analyze large-scale real-world evidence without exposing patient identity.
VisitVizor LEAD Research Initiative
Medicine advances when we understand what actually happens across real patients, real treatments, and real time. VisitVizor LEAD helps make that possible through patient-held continuity, patient-directed consent, and real-world longitudinal evidence at scale.